Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.58 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | RORB | Q92753 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724251 | 0.84 | PTPN5 (0.43) | PTPN5PDK2PGRARRORB | |
| SCHEMBL17974911 | 0.83 | HTR7 (0.40) | PTPN5PDK2ARRORBRORC | |
| SCHEMBL1133453 | 0.78 | PTPN5 (0.69) | PTPN5PDK2PGRARRORB | |
| SCHEMBL17974916 | 0.73 | MAOB (0.41) | PDK2PGRARAKR1C3 | |
| SCHEMBL17974909 | 0.73 | NR1H2 (0.44) | PTPN1 | |
| SCHEMBL17974819 | 0.72 | AKT1 (0.40) | PDK2 | |
| SCHEMBL20724250 | 0.72 | PTPN5 (0.37) | PTPN5HTR7 | |
| SCHEMBL17974974 | 0.72 | TSHR (0.52) | — | |
| SCHEMBL17974910 | 0.72 | MKNK1 (0.44) | PDK2 | |
| SCHEMBL26556078 | 0.71 | HTR7 (0.64) | PTPN5PDK2PGRARHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | PTPN5 3893/4885PDK2 3140/4885PGR 3933/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | PTPN5 3893/4885PDK2 3140/4885PGR 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.